Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 1155979 | DNA polymerase activity in rheumatoid synovial membranes. | 1975 Jun | RNAase-sensitive DNA polymerase activity was demonstrated in synovial membrane preparations from 23 out of 25 rheumatoid arthritis patients. Control groups consisted of twelve patients with osteoarthrosis, four with secondary osteoarthrosis, and twelve with other conditions. The last group showed no activity, while the results with the other two groups were varied. The properties of the polymerase enzyme, such as its stimulation by synthetic templates and inhibition by actinomycin D, were not consistent with it being associated with an oncogenic virus; it seems to be more like that found in stimulated normal human lymphocytes, described as an RNA-primed DNA-directed DNA polymerase. | |
| 6880404 | Cultivation of fastidious mycoplasmas from human arthritis. | 1983 Mar | 14 joint fluid specimens from arthritic patients and 8 synovial tissue specimens from traumatic joint lesions were studied for mycoplasmas. Fastidious slow-growing mycoplasmas were cultivated from arthritic patients but not from the controls. Using a large field microscope and a lens correcting the thickness of the Dienes-stained agar block preparations, tiny granular colonies with a diameter of 15-50 micrometers were seen. The isolates were arginine-positive but glucose- and urea-negative. In growth inhibition tests there was a partial inhibition zone of 1-10 mm by M. hominis type 2 and M. arthritidis immune sera. Thus the isolates resembled mycoplasmas previously recovered from acute and chronic human arthritis in Finland. | |
| 3884715 | Cross-reactivity between solid-phase immunoassay plates and intermediate filaments demonst | 1985 Mar 18 | While screening supernatants of human-human hybridomas for rheumatoid factor and anti-cellular activity we found that a significant number of supernatants which react with the Falcon-polyvinyl chloride immunoassay plate used in an enzyme-linked immunosorbent rheumatoid factor assay also react with intracellular intermediate filaments. | |
| 6377249 | Diflunisal 500-750 mg versus aspirin 2600-3900 mg in the treatment of rheumatoid arthritis | 1984 May | Diflunisal was compared to aspirin in a 12-week, double-blind, parallel, multicenter rheumatoid arthritis study. One hundred twenty-six (126) patients received diflunisal and 123 patients received aspirin. Both treatment groups demonstrated significant improvement from baseline in joint pain, morning stiffness, grip strength, walking time and painful and swollen joint scores. For these parameters, the only statistically significant difference between the groups was that diflunisal was more effective than aspirin for overall joint pain at week 2. The overall evaluation by patients and by investigators showed significantly better responses in those treated with diflunisal at weeks 1 and 12. Diflunisal produced significantly less gastrointestinal pain and tinnitus than aspirin. Neither drug showed unusual frequency of adverse effects as determined in the laboratory. Long-term studies using a higher-dose regimen are suggested to further define the efficacy and tolerability of diflunisal in the treatment of patients with rheumatoid arthritis. | |
| 3877695 | Subclasses of human IgG anti-Fab antibodies: parameters for optimum detection. | 1985 | In this study we have defined the parameters needed for the optimum detection of anti-Fab antibodies in the serum of patients with rheumatoid arthritis. We have found that the majority of the anti-Fab antibodies are of the IgG3 and IgG4 subclasses which were not optimally detected using polyclonal heterologous anti-human IgG antisera; subclass-specific antibodies instead were needed. Additionally we determined that dissociation of circulating immune complexes by dialysis against urea for 3-7 days was also needed for the detection of these antibodies. Lastly we have shown that the dissociated complexes can recombine with their target Fab molecules, and therefore separation of the anti-Fab antibodies from the other immunoglobulins by chromatofocusing may enhance the detection of these antibodies. When the above conditions were fulfilled it was determined that IgG anti-Fab antibodies could be detected in rheumatoid arthritis and normal sera and that acidic IgG3 and IgG4 subclasses predominated. However, IgG3 levels were 10.5-fold higher in rheumatoid arthritis sera (p less than 0.05) and IgG4 levels 5-fold higher (p less than 0.01) than in normal sera. | |
| 3907900 | Human monoclonal antibodies from patients with rheumatoid arthritis: cross reactions again | 1985 Sep | Hybridization of peripheral blood lymphocytes from patients with rheumatoid arthritis has yielded 14 monoclonal antibodies which react with cultured human epithelial cells. Immunofluorescence staining identifies at last five different types of antibody. Solid phase immunosorbent assays show a variety of cross-reaction patterns with nucleic acids, proteoglycan, cardiolipin and plastic, confirming that the various antibodies react with epitopes which are at least slightly different. These conclusions are confirmed by SDS gel electrophoresis and immunoblotting on epithelial cell extracts. Similar antibodies previously found in association with lupus-like disease have been thought to be representative of the high antinuclear antibody response characteristic of lupus. Our data are more consistent with the hypothesis that all or many of these antibodies are part of the normal inflammatory response. | |
| 6345164 | Piroxicam suppositories for osteoarthritis and rheumatoid arthritis: an open multicentre s | 1983 | Efficacy and toleration of piroxicam suppositories 20 mg, given once daily for 4 weeks were assessed in 96 patients suffering from degenerative joint disease and 20 patients suffering from rheumatoid arthritis. The mean scores of objective parameters measured (tenderness, swelling, limitation of movement) decreased significantly 2 and 4 weeks after initiation of therapy. Patients' self-evaluation of pain and stiffness also significantly improved during the trial. Overall evaluation of efficacy and toleration were excellent or good in more than 80% of patients. Local toleration was excellent in all but two patients. | |
| 4586032 | Comparison of some murine and human amyloid preparations. | 1973 Oct | Amyloid fibres extracted from the spleen and liver of Swiss albino mice, in which amyloidosis was induced by repeated casein injections, and from SJL/J mice with amyloidosis secondary to spontaneous pleiomorphic reticulum cell sarcoma were compared with human amyloid secondary to rheumatoid arthritis and Hodgkin's disease. The murine preparations resembled human amyloid in the green birefringence after congo red staining. Fibrillar structures, single or pairs, 70 Ã… in diameter and 700-2200 Ã… in length, similar to human amyloid, were revealed by electron microscopy. On the other hand, a marked dissimilarity in the chemical composition of murine and human amyloid was observed. The murine preparation contained a high lipoprotein and DNA content while in human amyloid only trace amounts of lipoprotein were detected in amyloid secondary to rheumatoid arthritis. | |
| 7065739 | An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of t | 1982 | In chronic rheumatoid arthritis (RA), disease modifying drugs are used in an attempt to suppress the progressive damage to tissues and joints that is associated with active disease. Their success in achieving this goal is variable; responses vary from complete suppression of all signs and symptoms of RA to continued active disease, with progressive disability, despite prolonged therapy. Because disease activity almost always recurs after the therapy is stopped, early interruption of an effective therapy for any reason will make its benefit insignificant in a lifelong disease such as RA. Similarly, short-term sequential use of multiple disease modifying therapies is unlikely to be beneficial. The immediate problems with these therapies are substantial. In general, fewer than 50% of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months or longer to achieve maximum effects, those patients who are unable to continue the drug receive little benefit from it. Inevitable delayed side-effects, such as those associated with chronic corticosteroid therapy, may make the benefit/risk ratio unacceptable. Potential late lethal adverse effects, such as malignancy, weight the benefit/risk ratio to varying extents for individual patients, depending on the relative probability that the adverse effect will occur during the remainder of the patient's anticipated life span, and are of greater importance in younger patients. In that minority of patients who achieve remission or near remission and are able to tolerate a disease modifying treatment for many years, it is of truly significant benefit. We are still searching for a therapy that will reliably achieve this goal for most patients with RA. | |
| 4049019 | The treatment strategies of arthritis sufferers. | 1985 | This paper describes and analyses the reasons for variation in the treatment strategies used by arthritis sufferers. The research was undertaken among 103 people from the Australian city of Perth. Qualitative data was obtained from a clinical sample of 27 and, on the basis of that, an interview schedule was constructed and administered to a survey sample of 76 self-reported arthritis sufferers. Data collected included comprehensive case histories, knowledge and beliefs about arthritis, types of practitioners consulted and treatments used and a range of demographic and socioeconomic variables. On the basis of analysis, four basic treatment strategies were discerned. Named after their most salient characteristics and ranging from least to most inclusive these were 'general practitioner and/or self care', 'medical and paramedical care', 'medical and alternative care' and use of 'all sources of care'. The most important determinants of treatment strategy were characteristics of disease--severity, mode of onset and period since onset. The longer the period since onset, the wider the range of treatments utilized. When onset occurred at a relatively young age and when progression was rapid, the more frequently alternative services and treatments were employed. Disease characteristics were followed in importance by socioeconomic factors. Use of the less inclusive strategies was related to social class; with working class people relying primarily on 'general practitioner and/or self care' and middle class people using 'medical and paramedical care'. However, when onset and progression were rapid, the disease was severe and the person relatively young socioeconomic factors were of lesser importance and people from all classes made use of the more inclusive strategies.(ABSTRACT TRUNCATED AT 250 WORDS) | |
| 56939 | Serum and synovial fluid inhibitors of antibody-mediated lymphocytotoxicity in rheumatoid | 1976 Mar | Many sera from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) inhibit lymphocyte-dependent antibody cytotoxicity (LDAC). RA synovial fluids also inhibit LDAC. RA serum inhibition was present in high molecular weight and 5S serum fractions, whereas in SLE it was confined to 7S fractions. A correlation between rheumatoid factor activity and LDAC inhibition was noted, and there was some evidence for inhibition of SLE serum acting on effector cells. Inhibition in RA synovial fluid was found in both high molecular weight and very low molecular weight fractions (less than 4S.) | |
| 6312543 | Antibodies to Epstein-Barr virus associated antigens in Pima Indians with and without rheu | 1983 | We investigated anti-rheumatoid arthritis-associated nuclear antigens (RANA) and other anti-Epstein-Barr virus (EBV) antibodies in a uniquely controlled study in female Pima Indians of Arizona, an RA prone population. Four groups of age and sex-matched individuals were formulated: (1) individuals positive for rheumatoid factor (RF) who had clinical evidence of rheumatoid arthritis (RA); (2) individuals seropositive for RF, but without arthritis; (3) individuals seronegative for RF, but with various kinds of arthritis; (4) those seronegative without arthritis. The mean anti-RANA in the seropositive RA group was significantly above those of the other groups but the anti-VCA and anti-EBNA titers did not differ. The anti-RANA was shown to be independent of RF. Comparing the Pima Indians to Caucasians in La Jolla, we found the mean anti-RANA titers of the Pimas to be significantly higher than those of the Caucasians. This study thus establishes clearly that elevated anti-RANA titers are characteristics of this American Indian group, just as they are of Caucasian groups. The elevated anti-RANA titers in RA patients may represent a unique hyperresponsiveness to this antigen, since there is no consistency in the reported levels of antibodies to other EBV-related antigens. | |
| 1083239 | Antibody-mediated lymphocytotoxicity in rheumatoid arthritis and systemic lupus erythemato | 1976 Mar | Lymphocyte-dependent antibody cytotoxicity (LDAC) was studied using peripheral blood and in some instances synovial fluid cells from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). No difference from normal controls was observed with peripheral blood lymphocytes from either RA or SLE. Marked decrement in LDAC effector cell activity was present particularly with RA synovial fluid cells. Sera from patients with RA or SLE as well as RA synovial fluids markedly inhibited LDAC. | |
| 7152741 | Some observations and speculations on the factors influencing the concentration of phenylb | 1982 Dec | Simultaneous plasma and synovial fluid samples have been obtained from patients, having reached a steady state on phenylbutazone, as a means of investigating factors influencing drug penetration into synovial fluid. Synovial fluid levels are lower than, but related to, plasma levels and are higher in rheumatoid disease (55-100% plasma levels) than in osteoarthritis (less than 50%). Patients with a more active form of the disease have higher synovial fluid drug concentrations. Results are discussed in the light of present knowledge and areas for further study are proposed. | |
| 7280484 | Thermography in the assessment of peripheral joint inflammation--a re-evaluation. | 1981 May | The reproducibility and sensitivity of quantitative infra-red thermography as a measure of peripheral joint inflammation was reassessed. Experiments were carried out in a temperature-controlled room at 20 degrees C. Initial stabilization experiments showed that in normal, medium sized, joints, there was an initial rapid cooling phase followed by a slower cooling phase which lasted longer than two hours. In the knees the differences between normal and active rheumatoid joints increased the longer patients remained in the room but for practical reasons a 30-minute stabilization period was subsequently chosen. In views of hands and fingers, rebound increases in skin temperature after entering the room, together with lesser differences between inflamed and non-inflamed joints, were found. The results suggested that the thermographic technique examined was adequate for detecting inflammatory changes in knee, ankles and elbows but unsatisfactory for quantification of inflammation in the small joints of the hands. | |
| 6419601 | Auranofin: experience to date. | 1983 Dec 30 | Auranofin, an oral gold-containing medication for the treatment of rheumatoid arthritis, has unique chemical, pharmacologic, and kinetic characteristics. Clinical improvement is achieved with lower blood gold levels than with parenteral gold compounds. More than 3,000 patients with rheumatoid arthritis in 27 countries have been treated with auranofin to date. In many patients, experience with auranofin extends beyond three years, and in some it exceeds four years. Available information indicates that auranofin (3 mg twice a day) is superior to placebo therapy, with similar efficacy and greater safety than gold sodium thiomalate. | |
| 3998418 | Correction of rheumatoid swan-neck deformity by lateral band mobilization. | 1985 May | Fifty-seven digits in 18 hands of 14 patients with rheumatoid disease were retrospectively evaluated after surgical correction of swan-neck deformity. Release of each hyperextension deformity was done via a previously described lateral band mobilization technique with temporary pin fixation of the proximal interphalangeal (PIP) joint and primary skin closure. Extension block splinting was used for 1 month after pin removal. Follow-up averaged 24 months. Twenty-two percent of the patients were enthusiastic about their results, 56% were satisfied, 22% were equivocal, and none were dissatisfied. Maximum active flexion at the PIP joint averaged 55 degrees, and maximum extension averaged--10 degrees. The average distance from fingertip to distal palmar crease was 32 mm. Average grip strength was 10 kg of force in men and 4 kg in women. Step-cut lengthening of the central slip was associated with the development of a boutonniere deformity and an unsatisfactory result in three digits. Even with narrowing of the PIP joint or articular erosions, which were found on 91% of roentgenograms, lateral band mobilization to correct swan-neck deformity can predictably improve the function and cosmesis of rheumatoid hands. | |
| 6266819 | A case of insulin autoimmune syndrome associated with small insulinomas and rheumatoid art | 1980 Dec | Twenty five cases of insulin autoimmune syndrome including this case has been reported so far without having the pathogenesis clarified. This paper describes a case which suggests one aspect of pathogenesis. The patient, a housewife concurrently had insulinoma and severe rheumatoid arthritis, complaining of hypoglycemic syncope attacks. During the attacks her blood sugar levels ranged from 19 to 22 mg%. Her serum extractable immunoreactive insulin (IRI) and insulin binding antibody levels were 557 microunits/ml and 0.390 mU/ml, respectively. gamma-Globulin-bound insulin was also measured electrophoretically. Bio-Gel P 10 column chromatography eluted almost all IRI at the void volume at pH 7.4 and a smaller but significant IRI peak also at pH 3.0. Selective angiography revealed a tumor-like staining in the pancreas body. Pancreatectomy relieved her of hypoglycemic attacks. Histology disclosed two small insulinomas. Insulinoma, rheumatoid arthritis and insulin autoimmune syndrome coexisted in this case, suggesting some causal relationship among them. | |
| 956395 | The cytotoxicity of leukocytes and lymphocytes from patients with rheumatoid arthritis for | 1976 Sep | Unseparated peripheral blood leukocytes obtained from patients with rheumatoid arthritis (RA) were cytotoxic for synovial cells. The cytotoxic reactions produced by RA leukocytes were more frequent and of greater magnitude than cytotoxicity induced by leukocytes from normal persons and patients with other diseases, primarily connective tissue diseases. Furthermore, the cytotoxic activity of RA leukocytes was greater for RA synovial cells than for nonrheumatoid synovial cells, in contrast to the cytotoxicity of other leukocytes, which did not discriminate between synovial cells according to their origin. Tests with purified lymphocytes showed that the cytotoxicity of unseparated leukocytes directed against RA synovial cells was due to lymphocyte cytotoxicity. These data are consistent with the possibility that sensitized lymphocytes from patients with RA recognize a distinctive antigen present on rheumatoid synovial cells. | |
| 7002066 | Antirheumatic activity of fenclofenac. | 1980 Oct | This study has set out to establish whether fenclofenac has an antirheumatic effect in addition to its anti-inflammatory and analgesic activity. The results show that during the course of a 6-month study the drug improved clinical parameters, including the articular index, early morning stiffness, ring sizes, and grip strength, and produced changes in laboratory measurements such as the levels of C-reactive protein, IgG, and rheumatoid factor. |